Nyxoah SA

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nyxoah reports mixed Q1 results, eyes strategic growth in 2023

Nyxoah's Q1 performance showed mixed results but with positive developments in the DREAM study and commercial rebound in Q2. The company aims for strategic growth in 2023 through market expansion and study advancements.

Nyxoah reports Q2 revenue growth, eyes FDA approval for U.S. market

Nyxoah's Q2 performance showed revenue growth and ongoing investments in market expansion. The company's strengths lie in Genio's features and upcoming milestones. Addressing challenges and seizing opportunities will be key for Nyxoah's future success.

Nyxoah reports Q3 revenue growth, eyes FDA approval by 2024

Nyxoah's Q3 performance reflects progress in key strategic areas, with a focus on patient-centric approaches and market expansion.
While facing challenges in managing expenses and regulatory timelines, the company is well-positioned for future growth and FDA approval by late 2024.
Opportunities lie in market expansion, partnerships, and innovative approaches to drive revenue growth and market penetration across regions.
Overall, Nyxoah's earnings call highlights a mix of strengths, challenges, and opportunities that shape its path towards leadership in the sleep disorder market.

Nyxoah SA reports robust Q4 sales and strategic 2024 plans

Nyxoah SA's Q4 2023 performance showcased strong sales growth and strategic accomplishments, setting the stage for future expansion.
While facing challenges in operating loss and cash burn, the company's financial position and upcoming milestones offer opportunities for growth.
Strategic partnerships and market positioning highlight Nyxoah's strengths in innovation and market differentiation.
Addressing market challenges and leveraging opportunities can drive Nyxoah's path towards profitability and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A. (NASDAQ:NYXH ) Q3 2022 Results Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Jeremy Feffer - Vice President, Investor Relations Olivier Taelman - Chief Executive Officer Loïc Moreau - Chief Financial Officer Conference Call Participants Simran Kaur - Piper Sandler Jonathan Block - Stifel Nicolaus Ross Osborn - Cantor Fitzgerald Operator Good day.

Nyxoah S.A. (NYXH) Q3 2022 Results - Earnings Call Transcript

Nyxoah A nnounces C hange to Board of Directors

Nyxoah Announces Change to Board of Directors

Nyxoah to Release Third Quarter Financial Results on November 8 , 2022

Nyxoah to Release Third Quarter Financial Results on November 8, 2022

Mont-Saint-Guibert, Belgium – August 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the 17th Annual Wells Fargo Securities Healthcare Conference, which takes place September 7-9, 2022, in Everett, MA. Nyxoah management will host one-on-one meetings with investors on Friday, September 9.

Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference

Nyxoah S.A. (NASDAQ:NYXH ) Q2 2022 Results Conference Call August 8, 2022 4:30 PM ET Company Participants Jeremy Feffer - VP, IR Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Simran Kaur - Piper Sandler Suraj Kalia - OpCo Operator Good day, and thank you for standing by.

Nyxoah S.A. (NYXH) CEO Olivier Taelman on Q2 2022 Results - Earnings Call Transcript

The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 170.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Nyxoah SA (NYXH) Could Rally 170%: Here's is How to Trade

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test

Mont-Saint-Guibert, Belgium – July 27, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the Canaccord Genuity 42nd Annual Growth Conference, which will take place in Boston, Massachusetts, from August 8 to 11, 2022.

Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference

Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022

The next generation external activation chip leverages Nyxoah's scalable platform to continuously enhance patient comfort and therapy efficacy

Nyxoah Announces CE Mark Approval for Genio® 2.1

Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Nyxoah SA (NYXH) Stock Jumps 13.2%: Will It Continue to Soar?

The FDA has approved Nyxoah SA's (NASDAQ: NYXH) Investigational Device Exemption (IDE) to initiate a trial, called ACCCESS, to evaluate the Genio system for moderate-to-severe Obstructive Sleep Apnea (OSA) and Complete Concentric Collapse (CCC) of the soft palate.  The FDA.

FDA Signs Off Nyxoah's Genio Trial In Complete Concentric Collapse Patients

Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients

Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index

FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study

Nyxoah Reports First Quarter 2022 Financial and Operating Results

REGULATED INFORMATION May 6, 2022, 7:00am CET / 1:00am ET

Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 8, 2022

Nyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors

Nyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022

Nyxoah Reports Full Year 2021 Operating and Financial Results

Nyxoah (NYXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Nyxoah (NYXH) Ahead of Earnings?

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts

Nyxoah to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Nyxoah to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Nyxoah to Present BETTER SLEEP Data, Host Physician Events at World Sleep Congress 2022

News for Nyxoah SA Stock (NYXH)